Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Immunovant (IMVT) Tax Provisions (2018 - 2026)

Immunovant filings provide 8 years of Tax Provisions readings, the most recent being $1.6 million for Q4 2025.

  • Quarterly Tax Provisions rose 921.05% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, up 575.7% year-over-year, with the annual reading at $891000.0 for FY2025, 57.14% up from the prior year.
  • Tax Provisions hit $1.6 million in Q4 2025 for Immunovant, up from $594000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $1.6 million in Q4 2025 and bottomed at -$991000.0 in Q1 2023.
  • Average Tax Provisions over 5 years is $229578.9, with a median of $152000.0 recorded in 2024.
  • The largest annual shift saw Tax Provisions tumbled 8158.33% in 2023 before it skyrocketed 1085.71% in 2025.
  • Immunovant's Tax Provisions stood at -$31000.0 in 2021, then soared by 1348.39% to $387000.0 in 2022, then plummeted by 127.91% to -$108000.0 in 2023, then skyrocketed by 240.74% to $152000.0 in 2024, then surged by 921.05% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Tax Provisions are $1.6 million (Q4 2025), $594000.0 (Q3 2025), and $913000.0 (Q2 2025).